Relvar(R) Ellipta(R) 100/25 mcg gains approval in Japan for use in patients with COPD
GlaxoSmithKline and Innoviva announced the Japanese MHLW has approved Relvar® Ellipta® (fluticasone furoate / vilanterol 100/25 mcg) for relief of various symptoms with COPD (in the case where concurrent use of inhaled corticosteroid and long-acting inhaled beta2 agonist is required). December 02, 2016